Zacks Investment Research Upgrades ABCAM PLC/ADR (OTCMKTS:ABCZY) to “Hold”

ABCAM PLC/ADR (OTCMKTS:ABCZY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday, Zacks.com reports.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Separately, ValuEngine lowered shares of ABCAM PLC/ADR from a “buy” rating to a “hold” rating in a research report on Friday, June 21st.

Shares of ABCZY stock traded down $0.65 during trading hours on Thursday, reaching $14.19. 4,698 shares of the company were exchanged, compared to its average volume of 724. ABCAM PLC/ADR has a fifty-two week low of $12.52 and a fifty-two week high of $20.29. The stock’s fifty day moving average is $16.42 and its two-hundred day moving average is $16.95.

About ABCAM PLC/ADR

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

Recommended Story: What is total return in investing?

Get a free copy of the Zacks research report on ABCAM PLC/ADR (ABCZY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ABCAM PLC/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABCAM PLC/ADR and related companies with MarketBeat.com's FREE daily email newsletter.